Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above 200-Day Moving Average – Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.66 and traded as high as $4.41. Cumberland Pharmaceuticals shares last traded at $4.36, with a volume of 33,426 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 6th.

Cumberland Pharmaceuticals Trading Up 3.1 %

The company has a 50 day simple moving average of $4.58 and a two-hundred day simple moving average of $2.66. The firm has a market cap of $60.90 million, a PE ratio of -5.66 and a beta of -0.18. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.99 and a current ratio of 1.13.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%. The company had revenue of $10.44 million for the quarter.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Two Sigma Investments LP raised its position in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) by 94.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,649 shares of the specialty pharmaceutical company’s stock after purchasing an additional 18,271 shares during the quarter. Two Sigma Investments LP owned about 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent SEC filing. Institutional investors own 15.51% of the company’s stock.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.